Abstract
Apoptosis dysregulation is a distinct hallmark of several disorders like systemic lupus erythematosus (SLE). In fact, SLE has two special features for apoptosis: irregular apoptosis and decline in clearing of apoptotic bodies. Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) is a death ligand that causes to apoptosis via attaching to its receptors such as death receptor-4 (DR4). The present study aimed to evaluate the effects of TRAIL G1525A and C1595T and DR4 A683C (rs20576) gene polymorphisms on SLE development. 160 SLE patients and 160 healthy individuals as the control group participated in the study. Genotype analysis was performed using polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). With regard to TRAIL (C1595T) polymorphism, the frequency of CT genotype was significantly higher in the case group than the control with 3-fold increase in SLE development risk (P = 0.0001). Furthermore, the frequency of the TT genotype also was higher in the case group than the control group with 3.2-fold increase in SLE development risk. The allelic distribution analysis defined the T allele as a risk factor for SLE development (P = 0.0001). The frequency of AA genotype and allele A of TRAIL (G1525A) polymorphism also was statistically higher in the case group than the control group (P = 0.0001). There was no significant association between DR4 rs20576 polymorphism and SLE development. TRAIL C1595T and G1525A gene polymorphisms are suggested as the risk factors for SLE development, although the results showed no association between DR4 rs20576 polymorphism and SLE.
Similar content being viewed by others
References
Anel A, Martinez-Lostao L (2011) APO2L/TRAIL: new insights in the treatment of autoimmune disorders. Recent Pat Inflamm Allergy Drug Discov 5:184–199
Bengtsson AA, Sturfelt G, Gullstrand B, Truedsson L (2004) Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus—an additional mechanism to increased autoantigen load? Clin Exp Immunol 135:535–543
Bouts YM et al (2012) Apoptosis and NET formation in the pathogenesis of SLE. Autoimmunity 45:597–601. https://doi.org/10.3109/08916934.2012.719953
Castellino G, Corallini F, Trotta F, Secchiero P (2007) Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies. Lupus 16:479–482. https://doi.org/10.1177/0961203307079455
Edgunlu TG, Ozge A, Yalin OO, Kul S, Erdal ME (2013) A study of the impact of death receptor 4 (DR4) gene polymorphisms in alzheimer's disease. Balkan Med J 30:268–272. https://doi.org/10.5152/balkanmedj.2013.7455
Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495–516. https://doi.org/10.1080/01926230701320337
Falschlehner C, Schaefer U, Walczak H (2009) Following TRAIL's path in the immune system. Immunology 127:145–154. https://doi.org/10.1111/j.1365-2567.2009.03058.x
Hakkim A et al (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 107:9813–9818. https://doi.org/10.1073/pnas.0909927107
Hashiramoto A et al (2018) A variant of death-receptor 3 associated with rheumatoid arthritis interferes with apoptosis-induction of T cell. J Biol Chem 293:1933–1943. https://doi.org/10.1074/jbc.M117.798884
Hu D et al (2015) Association of ulcerative colitis with TNF-related apoptosis inducing ligand (TRAIL) gene polymorphisms and plasma soluble TRAIL levels in Chinese Han population. Eur Rev Med Pharmacol Sci 19:467–476
Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ, Richardson BC (2002) The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol (Baltimore, Md: 1950) 169:6020–6029
Kikuchi S, Miyagishi R, Fukazawa T, Yabe I, Miyazaki Y, Sasaki H (2005) TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 167:170–174. https://doi.org/10.1016/j.jneuroim.2005.06.021
Koç Erbaşoğlu Ö, Horozoğlu C, Ercan Ş, Kara HV, Turna A, Farooqi AA, Yaylım İ (2018) Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer. Libyan J Med 14:1535746–1535746. https://doi.org/10.1080/19932820.2018.1535746
Korner C et al (2012) TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BMC Cancer 12:85. https://doi.org/10.1186/1471-2407-12-85
LeBlanc HN, Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10:66–75. https://doi.org/10.1038/sj.cdd.4401187
Lleo A, Selmi C, Invernizzi P, Podda M, Gershwin ME (2008) The consequences of apoptosis in autoimmunity. J Autoimmun 31:257–262. https://doi.org/10.1016/j.jaut.2008.04.009
Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M (2005a) Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 64:854–858. https://doi.org/10.1136/ard.2004.029058
Luo J, Xiong J, Wu J, Ye X (2015) Genetic polymorphisms and haplotypes of TRAIL gene correlate with NSCLC susceptibility in a group of Chinese patients. Int J Clin Exp Med 8:16223–16230
Makled AF, Elbrolosy AM, Awad ET, Elshebini EM, El Gedawy GA, Helwa M (2018) Tumor necrosis factor-related apoptosis inducing ligand in systemic lupus erythematosus patients; potential role in disease activity, neutropenia and renal impairment. Egypt J Med Microbiol 27:143–151
McHugh NJ (2002) Systemic lupus erythematosus and dysregulated apoptosis—what is the evidence? Rheumatology 41:242–245. https://doi.org/10.1093/rheumatology/41.3.242
Moudi B, Salimi S, Farajian Mashhadi F, Sandoughi M, Zakeri Z (2013) Association of FAS and FAS ligand genes polymorphism and risk of systemic lupus erythematosus. Sci World J 2013:176741. https://doi.org/10.1155/2013/176741
Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J (2008) Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 17:371–375. https://doi.org/10.1177/0961203308089990
Ndebele K, Gona P, Jin T-G, Benhaga N, Chalah A, Degli-Esposti M, Khosravi-Far R (2008) Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced mitochondrial pathway to apoptosis and caspase activation is potentiated by phospholipid scramblase-3. Apoptosis Int J Program Cell Death 13:845–856. https://doi.org/10.1007/s10495-008-0219-4
Nguyen V, Cudrici C, Zernetkina V, Niculescu F, Rus H, Drachenberg C, Rus V (2009) TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects. Clin Immunol (Orlando, Fla) 132:32–42. https://doi.org/10.1016/j.clim.2009.02.011
Petri M et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686. https://doi.org/10.1002/art.34473
Rai R, Sharma KL, Sharma S, Misra S, Kumar A, Mittal B (2014) Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population. PLoS ONE 9:e90264. https://doi.org/10.1371/journal.pone.0090264
Savill J, Dransfield I, Gregory C, Haslett C (2002) A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2:965. https://doi.org/10.1038/nri957
Sciascia S, Radin M, Roccatello D, Sanna G, Bertolaccini ML (2018) Recent advances in the management of systemic lupus erythematosus. F1000Research. https://doi.org/10.12688/f1000research.13941.1
Timirci-Kahraman O et al (2015) Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand and death receptor genes contribute to susceptibility to bladder cancer. Genet Test Mol Biomarkers 19:309–315. https://doi.org/10.1089/gtmb.2015.0050
Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365:2110–2121. https://doi.org/10.1056/nejmra1100359
Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628. https://doi.org/10.1038/sj.onc.1207232
Wang C et al (2015) Tumor necrosis factor-related apoptosis inducing ligand gene polymorphisms are correlated with gastric cancer in central China. Pharm Res 32:762–768. https://doi.org/10.1007/s11095-013-1217-y
Wang F, Zhang X, Wang Y, Sun Z (2016) Association of polymorphisms in TRAIL and Chronic Hepatitis B in Chinese Han Populations from Shandong Province. Ann Clin Lab Sci 46:374–379
Worth A, Thrasher AJ, Gaspar HB (2006) Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol 133:124–140. https://doi.org/10.1111/j.1365-2141.2006.05993.x
Wu YD, Lin CH, Chao WC, Liao TL, Chen DY, Chen HH (2017) Association between a history of periodontitis and the risk of systemic lupus erythematosus in Taiwan: a nationwide, population-based, case-control study. PLoS ONE 12:e0187075. https://doi.org/10.1371/journal.pone.0187075
Yan X et al (2009) sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease. Immunogenetics 61:551–556. https://doi.org/10.1007/s00251-009-0389-4
Yan H, Hong Y, Cai Y (2020) Association between FAS gene −670 A/G and −1377 G/A polymorphisms and the risk of autoimmune diseases: a meta-analysis. Biosci Rep. https://doi.org/10.1042/bsr20191197
Yu Y, Zhu C, Zhou S, Chi S (2018a) Association between C1q, TRAIL, and Tim-1 gene polymorphisms and systemic lupus erythematosus. Genet Test Mol Biomarkers 22:546–553. https://doi.org/10.1089/gtmb.2018.0056
Yu Y, Zhu C, Zhou S, Chi S (2018b) Association between C1q, TRAIL, and Tim-1 gene polymorphisms and systemic lupus erythematosus. Genet Test Mol Biomarkers 22:546–553
Acknowledgements
This project was supported by the Research Deputy in Zahedan University of Medical Sciences (IR. ZAUMS. REC.1396.268).
Author information
Authors and Affiliations
Contributions
SS: Methodology and manuscript writing; MS: patient management and designed the experiments; MS: supervision and writing; HS: performed the experiments and analyzed the data. All authors edited and approved the final version submitted for publication.
Corresponding author
Ethics declarations
Conflict of interest
We announce that we have no conflict of interest.
Ethical Approval
All proceedings performed in the present study containing human participants conform to the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consents were gained from the study subjects. Also, the study protocol was approved by the ethics committee of Zahedan University of Medical Science.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sandoughi, M., Salimi, S., Shahraki-Ghadimi, H. et al. The Impact of TRAIL (C1595T and G1525A) and DR4 (rs20576) Gene Polymorphisms on Systemic Lupus Erythematosus. Biochem Genet 58, 649–659 (2020). https://doi.org/10.1007/s10528-020-09966-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10528-020-09966-x